-
Good news! The ACR/ARP highlights are now available in Chinese
and Japanese
languages
http://rheumahighlights.com Get the most out of #ACR19!#rheumahighlights#rheumatology -
#ACR2019#acr19 new Guidelines OA:
exercise (aerobic/streng/neuroM/aquatic
)


weigth

tai chi
TENS
(no evidence)
topical/oral NDSAIDs/intraarticular GCs
intraarticular HyA (hip)
glucosamine and/or chondroitin
(Look slides 
) pic.twitter.com/Y76IECqkPJ
-
#tbt#ACR19 "Update in Myositis" session with tips on how to use the new classification criteria I honestly find them difficult and only reference in marginal cases Excellent tables from the presentation, though - great reference for antibodies and presentations!@RheumNowpic.twitter.com/SyzhLZHtcI
-
#tbt#ACR19 - Update in Myositis: Don't forget about toxin induced myopathy! Important mimickers related to treatment we give! 1. Steroid: myopathy w/o inflammation 2. Colchicine: vacuolar myopathy 3. Anti-malarial: vacuolar degeneration P.S. This might be good boards prep... pic.twitter.com/m48UkZlGP3
-
Presenting our poster "Antisynthetase Syndromes: Correlation of IIFA Patterns with Diagnosis Criteria Fulfillment" at
#ACR19 in Atlanta. Many thanks to@fmguanarteme,@MdicosLasPalmas and@SEReumatologia for contributing to this project and its presentation at this meeting.pic.twitter.com/jtIa7cApl9
-
Excited to share this
@CreakyJoints report of the big#ACR19 takeaways for patients, with lots of help from@rheum_cat@psufka@EBRheum@HealioRheum@RheumNow & others. Too much to pack into just one resource, so we have 6 wrap-up stories this year!https://creakyjoints.org/education/acr-2019-research/ … -
We’ve got another special Hot Topics episode available on the podcast! Join our host Dr. Hausmann, along with Dr. Ali Duarte Garcia and Dr. Suleman Bhana, as they discuss studies featured in
#ACR19 press conferences. https://acr.tw/32Na5F8 pic.twitter.com/1yVFUL5xX0
-
Multiple SS-clinical trial results presented at
#ACR19. The challenge to identify responders remains! Lots of interest for our abatacept follow-up data (week 48) presented by Jolien! pic.twitter.com/ayhnCLeiWs
-
Listen in for insights and highlights discussed during the podcast from the American College of Rheumatology 2019 conference,
#ACR19: Hear the results of the next promising and new treatments in#psoriaticarthritis and#spondyloarthritis http://bit.ly/3988yN8#ANRF -
Rt
@ACRheum: Episode 7 of ACR on Air looks at a few more studies featured during our#ACR19 press conferences. Listen at: https://acr.tw/32Na5F8 pic.twitter.com/x41hbnzuA6
-
Retrospective cohort study of 154 RA patients undergoing 244 major surgeries in shows that perioperative use of DMARDs (39%) or biologics (13%) was not associated with 30-day odds of post-operative infection
#ACR19 Abst #1805 http://bit.ly/34rmyie -
It’s a good day (& year!) for
#lupus#nephritis#patients - 1st we had positive#Nobility phase2 trial#obinutuzumab (@Roche) reported@ASNKidney#KidneyWk &#ACR19. & today, phase3#Voclosporin hits primary & secondary endpoints in#AURORA@AuriniaPharmahttps://ir.auriniapharma.com/press-releases/detail/164/aurinia-announces-positive-aurora-phase-3-trial-results …Prikaži ovu nit -
Management of GCA Guidelines from
#ACR19 (FIXED!): The presenter went quickly by the slide on methotrexate & the slide deck was not available during the presentation. Small update now that slides are available, MTX recs included: "[MTX] can be considered as initial treatment" pic.twitter.com/Cm7jBPeGZz
-
This is the best summary of
#ACR19 that I’ve seen. Great work putting this together@laurenbgelman and the rest of the@CreakyJoints community.@SethSaidSohttps://twitter.com/laurenbgelman/status/1198779600802844672 … -
I missed this one during
#ACR19 (found via@RheumNow's weekly roundup): Abstract L19: Early study, but BAFF inhibitor Ianalumab met its primary endpoint in primary Sjogren's.https://acrabstracts.org/abstract/ianalumab-vay736-a-dual-mode-of-action-biologic-combining-baff-receptor-inhibition-with-b-cell-depletion-for-treatment-of-primary-sjogrens-syndrome-results-of-an-international-randomized/ … -
spent several days in atlanta w/ my friends & colleagues
@Xtel007 &@SynceNerd_Carli. it’s taken many years of advocacy to reach this moment. thank you@acrheum for inviting patient advocates in such a meaningful way to author abstracts & present posters at#ACR19 #LupusChatpic.twitter.com/APQMT3YkZx
-
I wrote about being a first time patient at
@ACRheum#ACR19 . What an amazing experience, I WILL go again! Thank you@Arthritis_ARC for sponsoring me! Thank you@steveston_gal for being my mentor. Also thanks to those who came to see me speak!http://bit.ly/37hHwmD -
This is exiting progress for patient inclusion.
#ACR19 let's continue to advance patient perspectives in research#PPI. Patient partners from Canada & US, I invite you to do Patient Engagement In Research Scale (PEIRS) online survey. http://bit.ly/US-PEIRS-survey https://twitter.com/LLi_1/status/1193583574248804355 …pic.twitter.com/a82l8jBKbY
-
The gist:
#Hydroxychloroquine blood levels and thrombotic events in#SLE. Risk reduction may be 2-3 times higher than for aspirin in secondary prevention of vascular events. Need to define treat to target strategies.#ACR19@ACRheum@HealioRheum@RheumNow@HopkinsMedNewspic.twitter.com/J4kaDWKu21
-
Can the happiest subspecialists experience burnout?
Now back from #ACR19, I am rekindled with a new spark and inspiration thanks to each and every one of you!
Please read my article for @RheumNow on burnout in rheumatology: http://bit.ly/32OXCkb
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.